Literature DB >> 23423980

The emerging "hallmarks" of metabolic reprogramming and immune evasion: distinct or linked?

Irina Kareva1, Philip Hahnfeldt.   

Abstract

The role of the immune system in tumor elimination has been shown to be increasingly ambiguous, as many tumors not only escape recognition by the adaptive immune response but also even prime the immune cells to promote tumor growth. This effect is achieved through a number of mechanisms, which include both direct interference with the cells of the adaptive immune response and indirect immunosuppression achieved through modification of the tumor microenvironment. We propose that through upregulation of glycolysis and the consequent lowering of pH in the tumor microenvironment, tumors can take advantage of a pH control system, already exploited by specific immune cell subpopulations, to gain control of the immune system and suppress both cytotoxic and antigen-presenting cells. This is accomplished through the direct competition of tumor cells with actively proliferating glycolytic immune cells for glucose and indirectly through the creation by the tumor of a microenvironment that interferes with maturation and activation of antigen-presenting cells and naïve cytotoxic T cells. Immunosuppressive properties of an acidic microenvironment in the vicinity of the tumor can thus provide additional benefits for upregulation of glycolysis by tumor cells, suggesting that the two emerging "hallmarks of cancer," altered glucose metabolism and immune suppression, are in fact fundamentally linked.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423980     DOI: 10.1158/0008-5472.CAN-12-3696

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 2.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

3.  miR-142 controls metabolic reprogramming that regulates dendritic cell activation.

Authors:  Yaping Sun; Katherine Oravecz-Wilson; Sydney Bridges; Richard McEachin; Julia Wu; Stephanie H Kim; Austin Taylor; Cynthia Zajac; Hideaki Fujiwara; Daniel Christopher Peltier; Thomas Saunders; Pavan Reddy
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

Review 4.  Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

Authors:  Sun Ha Choi; Seung Soo Yoo; Shin Yup Lee; Jae Yong Park
Journal:  Arch Pharm Res       Date:  2022-04-21       Impact factor: 4.946

5.  Tumor cells and memory T cells converge at glycolysis: therapeutic implications.

Authors:  Swathi Karthikeyan; Jean-Francois Geschwind; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

6.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

7.  Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α.

Authors:  Sangbin Lim; Hao Liu; Luciana Madeira da Silva; Ritu Arora; Zixing Liu; Joshua B Phillips; David C Schmitt; Tung Vu; Steven McClellan; Yifeng Lin; Wensheng Lin; Gary A Piazza; Oystein Fodstad; Ming Tan
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

Review 8.  Hypoxia and acidosis: immune suppressors and therapeutic targets.

Authors:  Sultan Damgaci; Arig Ibrahim-Hashim; Pedro M Enriquez-Navas; Shari Pilon-Thomas; Albert Guvenis; Robert J Gillies
Journal:  Immunology       Date:  2018-03-30       Impact factor: 7.397

Review 9.  From mice to humans: developments in cancer immunoediting.

Authors:  Michele W L Teng; Jerome Galon; Wolf-Herman Fridman; Mark J Smyth
Journal:  J Clin Invest       Date:  2015-08-04       Impact factor: 14.808

10.  ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signaling.

Authors:  Tao Zhu; Juyan Zheng; Wei Zhuo; Pinhua Pan; Min Li; Wei Zhang; Honghao Zhou; Yang Gao; Xi Li; Zhaoqian Liu
Journal:  Cell Death Discov       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.